| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |




From the Retina Research Institute,* Massachusetts Eye and Ear Infirmary, and the Department of Adult Oncology,
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; the Eyetech Research Center,¶ Eyetech Pharmaceuticals, Woburn, Massachusetts; and the Department of Vitreoretinal Surgery,
Center of Ophthalmology, and Zentrum für Molekulare Medizin Köln,
the Center for Molecular Medicine University of Cologne, Cologne, Germany
Diabetic retinopathy is a leading cause of blindness in the Western world. Aberrant intercellular adhesion molecule-1 expression and leukocyte adhesion have been implicated in its pathogenesis, raising the possibility of an underlying chronic inflammatory mechanism. In the current study, the role of insulin-like growth factor (IGF)-I in these processes was investigated. We found that systemic inhibition of IGF-I signaling with a receptor-neutralizing antibody, or with inhibitors of PI-3 kinase (PI-3K), c-Jun kinase (JNK), or Akt, suppressed retinal Akt, JNK, HIF-1
, nuclear factor (NF)-
B, and AP-1 activity, vascular endothelial growth factor (VEGF) expression, as well as intercellular adhesion molecule-1 levels, leukostasis, and blood-retinal barrier breakdown, in a relevant animal model. Intravitreous administration of IGF-I increased retinal Akt, JNK, HIF-1
, NF-
B, and AP-1 activity, and VEGF levels. IGF-I stimulated VEGF promoter activity in vitro, mainly via HIF-1
, and secondarily via NF-
B and AP-1. In conclusion, IGF-I participates in the pathophysiology of diabetic retinopathy by inducing retinal VEGF expression via PI-3K/Akt, HIF-1
, NF-
B, and secondarily, JNK/AP-1 activation. Taken together, these in vitro and in vivo signaling studies thus identify potential targets for pharmacological intervention to preserve vision in patients with diabetes.
This article has been cited by other articles:
![]() |
V. Poulaki, E. Iliaki, N. Mitsiades, C. S. Mitsiades, Y. N. Paulus, D. V. Bula, E. S. Gragoudas, and J. W. Miller Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis FASEB J, July 1, 2007; 21(9): 2113 - 2123. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Fornoni, S. A. Rosenzweig, O. Lenz, A. Rivera, G. E. Striker, and S. J. Elliot Low Insulin-Like Growth Factor Binding Protein-2 Expression Is Responsible for Increased Insulin Receptor Substrate-1 Phosphorylation in Mesangial Cells from Mice Susceptible to Glomerulosclerosis Endocrinology, July 1, 2006; 147(7): 3547 - 3554. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Mitsiades, V. Poulaki, G. Fanourakis, E. Sozopoulos, D. McMillin, Z. Wen, G. Voutsinas, S. Tseleni-Balafouta, and N. Mitsiades Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin. Cancer Res., June 15, 2006; 12(12): 3705 - 3712. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Stephens, P. McElduff, A. H. Heald, J. P. New, J. Worthington, W. E. Ollier, and J. M. Gibson Polymorphisms in IGF-Binding Protein 1 Are Associated With Impaired Renal Function in Type 2 Diabetes Diabetes, December 1, 2005; 54(12): 3547 - 3553. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |